Myriad Genetics (MYGN) reported $213.1 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 0.8%. EPS of $0.05 for the same period compares to $0.05 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $201.9 million, representing a surprise of +5.55%. The company delivered an EPS surprise of +600%, with the consensus EPS estimate being -$0.01.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Myriad performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue by core product- Prenatal: $47.6 million compared to the $49.93 million average estimate based on three analysts. The reported number represents a change of +10.7% year over year.
- Revenue by core product- Hereditary Cancer: $96.3 million versus the three-analyst average estimate of $88.37 million. The reported number represents a year-over-year change of +5.3%.
- Revenue by core product- Pharmacogenomics: $37.8 million versus the three-analyst average estimate of $32.08 million. The reported number represents a year-over-year change of -12.1%.
- Revenue by core product- Tumor Profiling: $31.4 million versus the three-analyst average estimate of $31.31 million. The reported number represents a year-over-year change of -3.7%.
View all Key Company Metrics for Myriad here>>>
Shares of Myriad have returned -24.8% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Myriad Genetics, Inc. (MYGN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
